Department of Cardiology, Beijing An Zhen Hospital, Chaoyang-qu, China.
Department of Cardiology, Beijing An Zhen Hospital, Chaoyang-qu, China
BMJ Open. 2021 Jun 22;11(6):e043603. doi: 10.1136/bmjopen-2020-043603.
Left bundle branch area pacing (LBBaP) is a relatively new approach for physiologic pacing. A limited number of retrospective clinical studies, featuring small sample sizes, have shown that compared with right ventricular apex pacing (RVAP), the QRS duration of postoperative ECG in LBBaP patients is narrower and the cardiac systolic function is improved. However, there have been no randomised controlled trials (RCTs) evaluating the efficacy and safety of LBBaP in patients with atrioventricular block (AVB). Therefore, the current study intends to address the paucity in RCT data evaluating LBBaP versus RVAP in AVB patients.
This study is a single-centre, randomised controlled superiority trial to be conducted at the Cardiac Centre of Beijing Anzhen Hospital. From January 2021 to December 2023, 210 consecutive AVB patients meeting the inclusion criteria and receiving pacemaker implantation will be enrolled. Participants will be randomly divided into an experimental group (LBBaP) and a control group (RVAP) at a 1:1 ratio. The primary outcome is left ventricular ejection fraction (LVEF), which will be assessed by echocardiography. The secondary outcomes in this study are synchrony of left ventricular systole, NT-proBNP, LVEDD, the 6-min walk distance, quality of life (SF-36 scale), all-cause mortality, cardiovascular death events, rehospitalisation rate and major complication rate.
This study was approved by the Medical Ethics Committee of Beijing Anzhen Hospital (No. 2020021X). The results of the trial will be presented at national and international conferences. We hypothesise that compared with RVAP, LBBaP will be superior for treating patients with AVB. This trial will provide evidence-based suggestion for the majority of electrophysiologists in pacing implantation.
ChiCTR2000034335.
左束支区域起搏(LBBaP)是一种相对较新的生理性起搏方法。少数回顾性临床研究显示,与右心室心尖部起搏(RVAP)相比,LBBaP 术后心电图的 QRS 时限更窄,心功能收缩功能得到改善,但这些研究样本量较小。目前尚无随机对照试验(RCT)评估 LBBaP 在房室传导阻滞(AVB)患者中的疗效和安全性。因此,本研究旨在填补 RCT 数据在评估 LBBaP 与 AVB 患者 RVAP 方面的空白。
本研究为单中心、随机对照优效性试验,将在北京安贞医院心脏中心进行。从 2021 年 1 月至 2023 年 12 月,符合纳入标准并接受起搏器植入的 210 例连续 AVB 患者将被纳入研究。参与者将以 1:1 的比例随机分为实验组(LBBaP)和对照组(RVAP)。主要结局为超声心动图评估的左心室射血分数(LVEF)。次要结局包括左心室收缩同步性、NT-proBNP、LVEDD、6 分钟步行距离、生活质量(SF-36 量表)、全因死亡率、心血管死亡事件、再住院率和主要并发症发生率。
本研究经北京安贞医院医学伦理委员会批准(编号 2020021X)。试验结果将在国内和国际会议上公布。我们假设与 RVAP 相比,LBBaP 对治疗 AVB 患者更具优势。该试验将为大多数电生理学家在起搏植入方面提供循证建议。
ChiCTR2000034335。